Background: Lubricin, or proteoglycan 4 (PRG4), is a glycoprotein responsible for joint boundary lubrication. PRG4 has been shown previously to be down-regulated after traumatic joint injury such as a meniscal tear. Preliminary evidence suggests that intra-articular injection of PRG4 after injury will reduce cartilage damage in rat models of surgically induced posttraumatic osteoarthritis.
Lubricin, or proteoglycan 4 (PRG4), is a mucinous glycoprotein found in synovial fluid that is expressed by the tissues lining synovial joints, binds to the articular cartilage surfaces, and serves in part as a boundary lubricant. 12 After joint trauma (eg, meniscal injury, anterior cruciate ligament [ACL] tear) or joint surgery (eg, partial meniscectomy, meniscal repair), PRG4 expression is down-regulated and the concentration in synovial fluid is reduced. 9, 11, 25, 37 Therefore, joints that have been traumatized by injury or surgery are at risk for arthrosis, possibly due to increased friction, which in turn may promote cartilage breakdown. 11, 25, 26, 47 Given that PRG4 expression is downregulated and that the PRG4 concentration in synovial fluid is reduced after joint injury, 37 intra-articular injections of recombinant human lubricin (rhPRG4) (ie, tribosupplementation) could potentially prevent disease progression. rhPRG4 has been shown to have similar properties as native PRG4 in that rhPRG4 binds to the articular cartilage surfaces and acts as a boundary lubricant. 1 Currently, viscosupplementation with hyaluronan (HA), another component of synovial fluid, is a US Food and Drug Administration (FDA)-approved therapy to treat symptoms associated with osteoarthritis. Although clinical evidence shows that intra-articular injections of HA provide short-term pain relief due to its anti-inflammatory properties, its disease-modifying effects remain doubtful. Only 1 clinical study, out of several, reported an increase in cartilage thickness after high-molecular-weight HA treatment. 18, 49 Although some investigators have proposed a synergistic interaction between PRG4 and HA ex vivo, 1, 7, 21, 30 the role of this interaction in vivo remains controversial. 6, 47 Studies have demonstrated that intra-articular injections of PRG4 and rhPRG4 have a chrondroprotective effect in small animal models of posttraumatic osteoarthritis. 15, 24, 26 The next step in translating rhPRG4 to clinical use for the treatment and prevention of posttraumatic osteoarthritis is to demonstrate its effectiveness in a large animal model. The first objective of the current study was to determine whether 3 weekly intra-articular injections of rhPRG4 after surgical destabilization of the medial meniscus (DMM) would reduce cartilage damage after 26 weeks in the porcine model. The second objective was to determine whether there was an added benefit of using rhPRG41HA in comparison to rhPRG4 alone, in vivo. It was hypothesized that the groups treated with injections of rhPRG4 or rhPRG41HA would have less cartilage damage than the group treated with placebo injection (phosphate-buffered saline [PBS]) after DMM and that injection of rhPRG41HA would result in improved outcomes compared with treatment with rhPRG4 alone. Joint integrity was evaluated by use of macroscopic (India ink) and microscopic (safranin O-fast green and hematoxylineosin) assessment. Secondary outcomes include the level of PRG4 in synovial fluid, the concentrations of a type II collagen breakdown marker (carboxy-terminal telepeptide of type II collagen [CTX-II]) in urine and serum, and the presence of an inflammatory cytokine (interleukin 1b [IL-1b]) in synovial fluid and serum.
METHODS

Study Design
The study was approved by the Institutional Animal Care and Use Committees of Brown University and Rhode Island Hospital and was performed to meet the ARRIVE (Animal Research: Reporting of In Vivo Experiments) guidelines. Thirty Yucatan minipigs (14 castrated males, 16 females; age, 13.5 6 0.79 months; weight, 55.5 6 2.1 kg) underwent unilateral destabilization of the medial meniscus and were randomized into 1 of 3 injection treatment groups: rhPRG4 (n = 10), rhPRG41HA (n = 10), and PBS (sham control, n = 10). The DMM model was selected because it is commonly used to induce osteoarthritis in small animal models 48 and because meniscal injuries are extremely common in humans. 14 The minipig model also exhibits features of osteoarthritis that are common to those seen in people. 29, 36 All animals were housed individually in adjacent pens for a minimum of 8 weeks at Brown University and then were transported to an offsite animal housing facility (Accuro Farms, Southbridge, Massachusetts). The minimum pen size was 22.5 sq ft.
Surgical Technique
After induction of general anesthesia (see Appendix Table A , available in the online version of this article), all animals underwent surgical DMM. The surgical knee was selected at random. An incision was made approximately 2 cm in length over the medial joint line at the medial edge of the patellar tendon. The dissection was carried through the subcutaneous and bursal tissues. Once through the capsule, part of the fat pad was excised and the incision was opened to expose the anterior horn of the medial meniscus. A snap was passed underneath the anterior horn of the medial meniscus to isolate this structure and protect the tibial cartilage during cutting. A 3-to 5-mm full-thickness segment of the anterior horn was then removed by use of a scalpel blade. Complete transection was confirmed via direct observation of retraction of the anterior portion of the meniscus relative to the cartilage of the tibial plateau and the medial femoral condyle. The wound was then irrigated with sterile PBS. The knee was closed in layers with buried sutures: arthrotomy: No. 0 Vicryl, interrupted; bursa: No. 2-0 Vicryl, running; subcutaneous tissue: No. 2-0 Vicryl, interrupted; and subcuticular layer: No. 3-0 Vicryl, interrupted. Postoperative pain was managed with a protocol (Appendix Table A ) that included buprenorphine, fentanyl, bupivacaine/lidocaine (incision site only after closure), and Tylenol elixir (as needed). Animals were treated with an antibiotic (ceftiofur) and an antivomiting agent immediately postoperatively (ondansetron). Animals were kept in pens for the duration of the study. They were not forced to exercise, although they appeared active when checked daily.
Intra-articular Injections
Full-length rhPRG4 was manufactured and provided by Lubris BioPharma. It was derived from Chinese Hamster Ovary (CHO) cells as previously described. 1, 43 The apparent molecular weight of 460 kDa, as assessed by dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE), is larger than its predicted molecular weight. 1 rhPRG4 is rich in Olinked Core 1 glycosylations 43 that are responsible for lubricating activity 27 and recapitulate native PRG4 lubricating activity on cartilage bearings in vitro. 1 The dosing strategy was scaled by weight based on previously published work on rodents, 26 which also used the same full-length rhPRG4 from CHO cells. For the rhPRG41HA preparation, a noncross-linked lyophilized HA preparation (R&D Systems), with a predicted molecular weight of~950 kDa, was mixed with the rhPRG4. The injection solutions (3 mL volume per injection with 0.1% Tween) were as follows: PBS, rhPRG4 (1.3 mg/mL), and rhPRG41HA (1.3 mg/mL rhPRG4 and 3 mg/mL HA). While animals were under general anesthesia, intra-articular injections were given 7, 14, and 21 days after surgery by use of ultrasound guidance (Logiq e; General Electric Healthcare). Animals were euthanized 26 weeks from surgery, and both hindlimbs were harvested. The surgical leg was immediately processed for testing, whereas the control knee was stored at 220°C.
Macroscopic Cartilage Assessment
The articulating surfaces of the medial tibial plateau and medial femoral condyle of the surgical limbs were stained with India ink and photographed for independent scoring by 2 blinded reviewers (B.C.F., K.A.W.). When a difference existed, the 2 scores were averaged. Scores ranged from 0 (smooth surface) to 4 (lesion with .10% exposed bone). 36, 44 In addition, the lesion areas were measured. The length and width of each lesion were measured by use of calipers, and the lesion area was approximated as an ellipse. 36 
Histological Assessment
Osteochondral specimens consisting of the medial compartment of the tibial plateau were dissected from the knee. They were fixed in 10% formalin for 7 days and then washed in PBS for 24 hours. Specimens were decalcified in EDTA for 7 months and embedded in paraffin. Slices 6 mm thick from the central region of the tibial plateau were obtained in the coronal plane. Histology slides were prepared for light microscopy by staining with safranin O-fast green to evaluate glycosaminoglycan content (scored 0-4), while an adjacent slice was stained with hematoxylin and eosin (H&E) to score cartilage structure (scored 0-10), chondrocyte density (scored 0-4), and cell cloning (scored 0-4). Note that a low score is indicative of minimal damage, while a high score is associated with severe damage. Three independent experienced examiners (K.A.W., B.C.F., G.D.J.), who were blinded to the animal number and experimental condition, scored the slides by consensus using a system that was adapted from that recommended for the sheep and goat by the Osteoarthritis Research Society International (OARSI). 31 The 4 subscores were reported independently and also were added to produce a total sum score (maximum possible score = 22).
Secondary Outcomes
Synovial fluid (without lavage), serum, and urine samples were obtained at the time of harvest. All samples were stored at 280°C until testing. Synovial fluid was recovered from the surgical knees of 8, 10, and 6 animals of the rhPRG4, rhPRG41HA, and PBS groups, respectively. All reagents, samples, and standards for the biochemical assays were prepared as instructed by the manufacturer and performed in triplicate.
PRG4 Enzyme-Linked Immunosorbent Assay
Relative comparisons of the PRG4 concentrations in the synovial fluid between treatment groups were determined using mAb 5C11 (EMD Millipore), a monoclonal antibody for PRG4, in an inhibition enzyme-linked immunosorbent assay (ELISA) format. 2 A standard concentration curve was constructed by diluting a concentrated rhPRG4 solution because we did not have purified porcine PRG4 available.
Carboxy-terminal Telepeptide of Type II Collagen
Concentrations of CTX-II, a type II collagen cleavage marker, were measured in urine and serum by use of the Cartilaps ELISA kit (Immunodiagnostic Systems IDS Inc). 47 Urinary CTX-II concentrations were normalized to urinary creatinine levels by use of the Creatinine Assay Kit (Abcam). 12 Normalized urinary CTX-II was reported as micrograms of CTX-II per nanomole of creatinine, and serum CTX-II was reported as picograms per milliliter.
Interleukin-1b
Concentrations of IL-1b in synovial fluid and serum were evaluated by means of a commercially available ELISA kit designed for swine (Thermo Scientific). 47 With a dilution factor of 10, the synovial fluid and serum concentrations were evaluated.
Statistical Methods
Nonparametric Kruskal-Wallis 1-way analyses of variance were used to compare treatment groups on macroscopic cartilage damage scores (medial tibial plateau and medial femoral condyle), histological damage scores (medial tibial plateau), and concentrations of PRG4, CTX-II, and IL-1b in the fluid samples. To control the type I error rate, we used exact Wilcoxon rank sum tests to make pairwise comparisons between groups when the Kruskal-Wallis tests indicated significant differences. Additionally, 1-way analysis of variance was used to compare mean lesion areas between treatment groups in the medial tibial plateau and lateral femoral condyle. All analyses were performed with SAS statistical software, version 9.4 (SAS Institute). Statistical significance was determined based on P \ .05. All data are presented as mean 6 SD.
Power for the macroscopic cartilage damage score was estimated to be 80% for detecting group differences with the Wilcoxon rank sum test when the probability that a randomly selected observation in one group was less than a randomly selected observation in the other group was equal to 0.85. This corresponds to a relatively large effect size.
RESULTS
Animal Welfare
All animals were fully weightbearing within 7 days of surgery and at the time of harvest. Twenty-nine of the 30 animals survived the 26-week follow-up period. One animal from the PBS group was fully weightbearing within 6 days of surgery; however, she refused food after surgery. She was euthanized 31 days after surgery as recommended by the veterinarian. Upon necropsy, it was determined by a veterinarian that the cause of anorexia appeared unrelated to any specific condition of the gastrointestinal tract or the surgery. This animal was excluded from the analysis.
Macroscopic Cartilage Assessment
All subjects showed macroscopic degenerative changes in the articular surfaces of the medial tibial plateau of the surgically treated knee ( Figure 1A ). Subjects receiving rhPRG4 treatment had significantly lower macroscopic scores in the medial tibial plateau compared with PBS control (P = .002) ( Figure  1B) , while there were no significant differences between the PBS-treated group and the rhPRG41HA group (P = .23). Likewise, no significant difference was found between the rhPRG4 and the rhPRG41HA groups (P = .070). All lesions were centrally located within the medial tibial plateau ( Figure 1A ). The mean lesions in the medial femoral condyles were similar in grade (2.1 6 0.77, 2.5 6 1.32, and 2.5 6 1.09 for the rhPRG4, rhPRG41HA, and PBS groups, respectively) to those in the medial tibial plateau but did not significantly differ between treatment groups (P = .75). The medial femoral condyle lesions were located in the anterior portion of the condyle, with some extending into the posterior region. Minimal damage was noted in the lateral compartment of the joint for all treatment groups. As for the mean lesion areas, no treatment group differences were found in the medial tibial plateau (rhPRG4, 22 6 19.0 mm 2 ; rhPRG41HA, 27 6 19.0 mm 2 ; PBS, 33 6 19.3 mm 2 ; P = .51) or the medial femoral condyle (rhPRG4, 6 6 19.0 mm 2 ; rhPRG41HA, 15 6 19.0 mm 2 ; PBS, 20 6 20.0 mm 2 ; P = .27).
Histological Assessment
No statistically significant differences were found in the mean histological sum scores of the medial tibial plateaus between groups (P = .70) ( Figure 2 ). The mean 6 SD of the sum scores were 15.5 6 3.95, 16.3 6 3.57, and 15.0 6 4.72 for rhPRG4, rhPRG41HA, and PBS groups, respectively. No differences were found between groups for any of the subscores (P . .26) ( Figure 3 ).
Secondary Outcomes
Elevated levels of PRG4 were observed in the synovial fluid of the rhPRG4 surgical limbs (n = 8) compared with those of the PBS group (n = 6, P = .033) ( Figure 4) . No differences were observed between the rhPRG4 and rhPRG41HA (n = 9) groups (P = .17) or between the rhPRG41HA and PBS groups (P = .09).
Urinary CTX-II concentrations were higher in the PBS (n = 9) and rhPRG41HA (n = 10) groups compared with the rhPRG4 group (n = 10, P = .013 and .011, respectively) ( Figure 5A ). However, serum CTX-II levels were not significantly different between groups (P = .94; Figure 5B ). Increased serum levels of IL-1b were found in the PBS (n = 9) compared with the rhPRG4 (n = 10, P = .006) and the rhPRG41HA groups (n = 10, P = .009), indicating the presence of systemic inflammation in the PBS-treated group ( Figure 6A) . No difference was observed between the rhPRG4 and rhPRG41HA groups (P = .791). Likewise, the surgical limb synovial fluids had elevated IL-1b concentrations in the PBS (n = 6) group compared with the rhPRG4 (n = 8, P = .017) and the rhPRG41HA (n = 9, P = .029) groups (Figure 6B) . No difference in IL-1b was observed between the rhPRG4 group and the rhPRG41HA group (P = .81).
DISCUSSION
The results of the study support the primary hypothesis that intra-articular injections of rhPRG4 would reduce arthrosis. Specifically, in the medial tibial plateau, the mean macroscopic score for the rhPRG4 group was significantly lower than that of the PBS group (Figure 1) . The reduction in macroscopic cartilage damage in the medial tibial plateau was likely due to the restoration of boundary lubrication and secondarily by anti-inflammatory activity. 4 However, differences were not evident in the medial femoral condyles. The porcine results agree with those of previous small animal studies after meniscal injury 15 and after ACL transection, 12, 13, 24, 26, 47 in which PRG4 supplementation reduced cartilage damage in treated knees in vivo. The CTX-II data, a marker of type II collagen cleavage, also support these findings as the rhPRG4 group had lower mean CTX-II levels in urine compared with the PBS group ( Figure 4A ), indicative of less systemic cartilage degradation. This finding also recapitulates similar observations in a prior small animal study. 26 The rhPRG4 group had reduced IL-1b levels in both the serum and synovial fluid, supporting less catabolic enzymatic activity in the cartilage. This group also showed the highest levels of synovial PRG4 after 26 weeks. In antigen-induced arthritis in rats, Elsaid et al 10 showed that PRG4 levels were diminished in arthritic joints immediately after induction of arthrosis. Furthermore, the loss of PRG4, which likely resulted from high levels of IL-1b and cathepsin B (a protease that degrades PRG4), leads to increased joint coefficients of friction. In a recent rat ACL transection study, intra-articular injections of rhPRG4 were found to significantly reduce the number of caspase-3-positive chondrocytes, thus preserving chondrocytes and possibly preventing cartilage degeneration. 12 Ruan et al 42 also observed decreased levels of CTX-II and less cartilage damage in arthritic mice after intra-articular injections of an adenoviral vector overexpressing PRG4. Most recently in transgenic mice, which conditionally express diphtheria toxin, it was shown that significantly diminishing the number of chondrocytes in a joint does not cause arthrosis 50 ; however, loss of chondrocytes occurs in PRG4-null mice. 28 All of these observations and the present findings indicate that PRG4 is crucial for preventing chondrocyte death and cartilage degeneration.
Our results did not support the secondary hypothesis that rhPRG41HA treatment would be more effective than treatment with rhPRG4 alone. While both treatment groups had reduced IL-1b levels in the synovial fluid and serum, the rhPRG4 group had less macroscopic cartilage damage than the rhPRG41HA group in the medial tibial plateau, and surprisingly, the rhPRG41HA group failed to show significant improvements over the PBS injection group ( Figure  1) . Studies have previously shown that the cartilage damage in PRG41HA-treated animals was similar to the damage in PRG4-injected rats. 47 It should be noted that the rat study used an HA formulation with a higher molecular weight (5000 kDa) than that used in the present study (~950 kDa). 47 For the present study, it was postulated that the lack of a difference may be attributed to the CD44-mediated anti-inflammatory effects of rhPRG4 and HA, in which both molecules compete for the cell-surface receptor CD44. 3 Additionally, a recent study in canines reported that viscosupplementation with 3 different doses of HA (2 dosing strategies with a high-molecular-weight HA [hylan G-F; molecular weight = 6000 kDa] and 1 dosing strategy with a low-molecular-weight HA [Hyalgan (Fidia Pharma USA Inc); 500-730 kDa]) provided symptomatic relief for posttraumatic osteoarthritis induced by radial transection of the medial meniscus; however, none of the doses reduced gross cartilage morphological or histological damage by 6 months compared with saline treatment. 38 One reason for these findings may have been the late timing of supplementation, which was initiated 4 months after surgery and may have been too late to reverse damage. Smith et al 45 also reported no significant differences in a canine ACL transection model in gross morphological or histological results or in gait at 12 weeks and 32 weeks after treatment with a low-molecular-weight HA (5 weekly injections of Hyalgan starting 1 day after surgery). The lack of differences between treatment groups (HA vs control) may be due to the low-molecular-weight formulation that was used.
Debate currently exists over whether rhPRG4 and HA function synergistically. Synergy has been reported in friction studies in which PRG4 or rhPRG4 is combined with HA to reduce joint friction in vitro. 1, 7, 33 In contrast, rhPRG4 and HA do not appear to be synergistic in vivo based on our current large animal study or our previous work in the ACL transection rat model. 47 The molecular weight of HA used in this study was~950 kDa and in the previous rat study it was 5000 kDa. 47 Although varying degrees of macroscopic cartilage damage were noted, microscopic histological scoring of medial tibial plateau lesions revealed no significant differences between groups. The lack of difference via histological testing is not surprising given that all 3 groups had significant chondral lesions in the medial compartment after DMM surgery, and the most severe region of the lesion was evaluated for each sample. While the data indicate that the macroscopic damage was less in the rhPRG4-treated group, the mean lesion damage in the medial tibial plateau was 1.8, where 1 indicates surface scuffing and 2 represents a significant lesion but with no bone exposure. 44 The histological assessment was performed through a central slice and encompassed the center of the lesion, which was present in the surgical limbs of all treatment groups. Furthermore, we created a mechanical defect in the meniscus that was left untreated. Thus, it is unlikely that full chondral protection would be possible. For example, partial meniscectomy has been shown to reduce meniscal hoop stresses, which are transferred to the bone through the meniscus roots in intact menisci. Thus, removal of the root would compromise meniscal function, decrease joint contact area, and increase joint contact pressure. 17 These biomechanical changes along with the associated increase of joint friction may ultimately lead to joint arthrosis. Nonetheless, it is noteworthy that the rhPRG4 injections were able to provide some long-term chondroprotection in light of this mechanical instability, and it seems plausible that rhPRG4 injections in combination with soft tissue repair (ie, meniscal root repair or meniscal repair) would further prevent chondral damage. Clinically, meniscal repair has been shown to lower the risk of posttraumatic osteoarthritis compared with partial meniscectomy. 34, 46 Future studies are being designed to address this issue.
DMM, full transection of the meniscus, or both are commonly performed in small animal models to study mechanisms of posttraumatic osteoarthritis and to evaluate potential disease-modifying therapeutics. 15, 20, 22, 23, 35 While these models provide significant insight into disease mechanisms and are relatively inexpensive compared with large animal models, findings regarding potential therapeutics should be validated in a larger animal model with a knee similar in size to the human joint. The porcine model was selected for this study as it has been shown to be anatomically and functionally similar to the human knee when compared with other animal models 39 and has been accepted by the FDA as a preclinical model to demonstrate the safety and efficacy of intra-articular ligament repair. 40 The DMM approach has been used with other large animal models such as sheep 8 and canines. 38 Cake et al 8 compared 3 different surgically induced meniscal injuries in sheep: (1) complete medial meniscectomy, (2) meniscal body transection, and (3) transection of the cranial meniscotibial ligament (cranial pole release). Gross morphological and histological assessment revealed that meniscal injury via the second and third surgical techniques produced significantly different scores compared with the sham group, but no significant differences were found between the surgically induced models. However, subtle differences were noted between the surgical methods regarding the location of the lesions. 8 In a recent canine study, arthroscopic destabilization of the medial meniscus was performed by making a radial transection at the posterior horn junction with the caudal meniscotibial ligament. 38 Four months later, the animals exhibited clinical signs of lameness. At 6 months, gross cartilage assessment revealed articular cartilage damage mainly in the medial compartment, and histological scores demonstrated that osteoarthritis had progressed in all animals. Compared with complete meniscectomy, DMM holds advantages in that a smaller incision can be made and the procedure time is shorter.
ACL transection in large animals has been used to initiate joint arthrosis in studies of posttraumatic osteoarthritis. 5, 36 In comparison to ACL transection, the porcine DMM model produced more consistent lesions, in both size and magnitude, located in the central region of the medial tibial plateau. The resulting mean 6 SD of the macroscopic scores of the untreated DMM group (PBS injection) was 2.8 6 0.57 at 26 weeks after surgery. The location of the lesions produced with our porcine DMM model was in agreement with those after medial meniscal body transection surgery in sheep at 12 weeks. 8 In our study, the animals exhibited significant macroscopic and histological cartilage lesions by 26 weeks. In a clinical study, Roemer et al 41 determined that patients who underwent partial meniscectomy showed radiographic signs of osteoarthritis within 1-year follow-up.
There are several study limitations to consider. A limitation of the DMM model was that the anterior horn was not mechanically repaired after it was cut. Thus, the DMM procedure would continue to promote long-term arthrosis despite early treatment with any short-term therapeutic agent. The rhPRG4 injections were completed within 4 weeks of surgery (1 injection per week) while joint integrity was assessed after 26 weeks. Therefore, it is not surprising that chondral damage was present in all treatment groups. Despite this limitation, the short-term rhPRG4 injections in this study showed evidence of slowing disease progression.
For the present study, we elected to study a lower molecular weight HA preparation (~950 kDa) in comparison to commercially available viscosupplements (~6000 kDa). Nonetheless, the HA preparation we used had a molecular weight reported to be useful in animal models 19 and was not a cross-linked viscosupplement. Unfortunately, a cross-linked HA would not have readily mixed with the rhPRG4. However, it was not the goal of this study to evaluate the performance of rhPRG4 in comparison to current viscosupplements. We only designed this study to check whether the addition of HA would further improve the performance of rhPRG4. 33 Thus, an HA-only group was not included. Nonetheless, the study results regarding HA could have been different if a higher molecular weight HA preparation had been used.
Another limitation is that we did not include a true control group. We elected not to use the contralateral knee since evidence indicates that minor cartilage damage occurs in the contralateral knee after surgical introduction of posttraumatic osteoarthritis in the porcine model. 36 Due to the prohibitive cost of large animal studies, we used the PBS-treated group as a positive control.
The relatively small sample size is another limitation to consider. The power analysis determined that we had sufficient power to detect group differences corresponding to relatively large effect sizes. Nonetheless, we were able to detect differences between the rhPRG4 and the sham (PBS) group.
Additional limitations are that the secondary analyses of synovial fluids between groups were of a lower sample size as we were unable to collect samples from all animals. This smaller sample size could potentially bias the results and/or limit the power of the synovial fluid analyses (ie, PRG4 and IL-1b). The values of the PRG4 concentration reported may not be fully accurate because purified rhPRG4 was used as a standard in ELISA due to a lack of purified porcine PRG4, which was not available. However, the relative comparison of PRG4 levels across the 3 treatment groups indicates that rhPRG4 may have restored native PRG4 expression. A measure of lameness was not included in this study, which could have provided insight into changes in joint function after treatment. Finally, another limitation in extrapolating our results to humans is that the pig is a quadruped. Nonetheless, there is evidence of anatomic and biomechanical similarities of the knee joint between pigs and humans. 29, 39 In conclusion, the study demonstrated that 3 weekly injections of rhPRG4 immediately after an acute joint injury attenuated cartilage damage in an in vivo preclinical model. Intra-articular injections of rhPRG4 decreased macroscopic cartilage damage in the medial tibial compartment, lowered a urinary biomarker of type II collagen breakdown (but not serum), and reduced the concentration of IL-1b in the synovial fluid and serum. Although rhPRG41HA-treated groups, which used an HA formulation of~950 kDa, exhibited low levels of IL-1b, this combination did not reduce cartilage damage compared with the positive control (PBS injection). Thus, rhPRG4 may provide a potential supplementation therapy to reduce posttraumatic osteoarthritis progression and warrants further study in an effort to translate the therapy to humans.
